RVMD · CIK 1628171
What Revolution Medicines, Inc. told the SEC could break it.
Revolution Medicines' disclosures are those of a pre-revenue biotech dependent on outside money and outside manufacturers. With a $2.9 billion accumulated deficit and no product revenue, it needs substantial additional financing, and an inability to raise it on acceptable terms could force it to delay, limit or terminate its development and commercialization efforts. It outsources all manufacturing to third-party CDMOs, some of which are its sole source of drug supplies — including key starting and intermediate materials — so an issue at one supplier could disrupt its development or commercial plans. That supply chain carries a China-policy overlay: it does business with Chinese companies referenced in BIOSECURE Act discussions, and the provisions enacted via the FY2026 NDAA could affect its collaborations, supply chains and manufacturing relationships.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue financing need ($2.9B accumulated deficit)high
As a clinical-stage company with a $2.9B accumulated deficit and no product revenue, Revolution Medicines requires substantial additional financing; inability to raise capital on acceptable terms could force it to delay, limit or terminate development/commercialization.
“We will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.”
SEC filing →As of 2026
Sole-source dependency
- sole-source CDMOs / drug-supply materialshigh
Revolution Medicines outsources all manufacturing to third-party CDMOs, and some third-party suppliers are its sole source of drug supplies (including key starting and intermediate materials); a supplier issue could delay development or commercial plans.
“Some of our third-party suppliers are currently our sole source of drug supplies (including key starting and intermediate materials) and, as a result, an issue with one of these suppliers may impact our development or commercial plans.”
SEC filing →As of 2026
Regulatory & policy
- BIOSECURE Act / China biotech restrictionsmedium
Revolution Medicines does business with companies in China referenced in BIOSECURE Act discussions; BIOSECURE provisions were enacted via the FY2026 NDAA (December 2025), and resulting lists/restrictions could materially affect its collaborations, supply chains, research partnerships and manufacturing relationships.
“We currently do business with companies in China, including some that have been referenced in earlier versions of the BIOSECURE Act and related policy discussions, and certain counterparties could be impacted by these legislative actions or regulatory lists. Changes in laws, regulations, or executive orders — or the issuance of lists identifying covered entities — could materially affect our collaborations, supply chains, research partnerships, manufacturing relationships, and access to certain services or technologies.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“If Tranches 2 through 5 are all purchased in their entirety, Royalty Pharma would be entitled to receive total Royalty Payments equal to 7.80 % of annual worldwide net sales up to $ 2.0 billion, 4.55 % of annual net sales between $ 2.0 billion and $ 4.0 billion, 2.40 % of annual net sales between $ 4.0 billion and $ 8.0 billion, and no Royalty Payments on sales in excess of $ 8.0 billion.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch